Ovarian granulosa cell tumors with bizarre nuclei: an immunohistochemical analysis with fluorescence in situ hybridization documenting trisomy 12 in the bizarre component corrected


     Related Videos
Genetics Counseling for Ovarian Cancer Risk
ECCO 15- ESMO 34 Berlin 2009 Cryopreservation of ovarian tissue
Finding Signs of Ovarian Cancer
Expert Response Ovarian Cancer
Patient Story Ovarian Cancer

     Related Hubpages

    •  Doc. Url:    Embed Code: 

    • PubMed  status
      (0) (0 Votes)
      Views: (2)   Date: (1996-3-1)   Pages: ()
    • Author:  R H Young  

    • Abstract:  Granulosa cell tumors with bizarre nuclei (GCT-BN) are rare lesions with a prognosis apparently similar to that of conventional granulosa cell tumors (GCT-NOS). The immunohistochemical features of GCT-BN have not been described, and the exact nature of the bizarre nuclei (BN) is unclear. Thirteen GCT-BN were studied with antibodies to cytokeratin, vimentin, epithelial membrane antigen, muscle-specific actin, alpha smooth muscle actin, desmin, and S-100 protein. Six cases were also examined by fluorescence in situ hybridization for trisomy 12, a nonrandom chromosomal aberration found in a proportion of ovarian sex-cord stromal tumors. Histologically, 12 tumors (86%) contained BN areas interspersed with large areas of GCT-NOS. The remaining tumor contained only microscopic foci of GCT-NOS. Immunohistochemicall y, the tumors stained for vimentin (13 tumors), S-100 protein (11 tumors), muscle-specific actin (10 tumors), cytokeratin (eight tumors), alpha smooth muscle actin (eight tumors), and desmin (one tumor), but none stained for epithelial membrane antigen. Immunostaining results for the BN and GCT-NOS areas were concordant in eight (73%) of the 11 tumors in which both areas could be independently assessed. The remaining three tumors (27%) showed discordant results for only one of the eight markers used. In five patients, trisomy 12 was detected by fluorescence in situ hybridization in areas of BN but not in areas of GCT-NOS present in the same tumor. Trisomy 12 was also present in another BN tumor in which the foci of GCT-NOS were too small to be evaluated. We conclude that within GCT-BN, areas with BN are immunohistochemicall y similar to areas of GCT-NOS present in the same tumor. The finding of trisomy 12 in areas with BN but not GCT-NOS in the same tumor, however, suggests that cells with BN represent a genetically distinct clone of tumor cells arising within GCT-NOS.

         Related Documents

           Related Groups

             Related Science News

               More on Sciencestage

                 Answers

                 News
            • Ovarian Cancer Canada names Dr. David Huntsman for inaugural research award
              TORONTO , Feb. 15, 2012 /CNW/ - Ovarian Cancer Canada has named Vancouver researcher Dr. David Huntsman as inaugural recipient of its Karen Campbell National Award for Research Excellence. The award recognizes ...
            • Ovarian Cancer Subtype May Be Vulnerable to Anti-Angiogenic Drugs
              Dana-Farber Cancer Institute researchers have identified a subtype of ovarian cancer able to build its own blood vessels, suggesting that such tumors might be susceptible to anti-angiogenic drugs. The investigators estimate that the subtype may account for a third of all serous ovarian cancers.
            • Ovarian cancer subtype may be susceptible to 'anti-angiogenic' drugs
              Scientists at Dana-Farber Cancer Institute have identified a subtype of ovarian cancer able to build its own blood vessels, suggesting that such tumors might be especially susceptible to "anti-angiogenic" drugs that block blood vessel formation.
            • Ovarian cancer screening popular despite guidelines
              NEW YORK (Reuters Health) - Despite expert guidelines and scientific evidence to the contrary, a third of U.S. primary care physicians believe ovarian cancer screening is effective and many would offer it to patients, according to a new survey. Although the results don't necessarily translate into real practice, that means more than a million women might be offered the tests, which come with a ...
            • Doxil/Caelyx (Ovarian Cancer) - Analysis and Forecasts to 2020
              NEW YORK, Feb. 8, 2012  /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Doxil/Caelyx (Ovarian Cancer) - Analysis and Forecasts to 2020 http://www.reportlinker.com/p0657184/Doxil/Caelyx-Ovarian-Cancer---Analysis-and-Forecasts-to-2020.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=PathologyDoxil/Caelyx ...
            • Study explains high platelets in ovarian cancer patients; survival reduced
              ( University of Texas M. D. Anderson Cancer Center ) Highly elevated platelet levels fuel tumor growth and reduce the survival of ovarian cancer patients, an international team of researchers led by scientists at the University of Texas MD Anderson Cancer center reports in the New England Journal of Medicine.
            • Research and Markets: Ovarian Cancer - Pipeline Review, H1 2012
              Research and Markets has announced the addition of Global Markets Direct's new report "Ovarian Cancer - Pipeline
            • Thrombocytosis linked to severity of ovarian cancer
              Highly elevated platelet levels fuel tumor growth and reduce the survival of ovarian cancer patients, an international team of researchers led by scientists at The University of Texas MD Anderson Cancer center reports in the New England Journal of Medicine.
            • New subtype of ovarian cancer may be vulnerable to anti-angiogenic drugs
              BOSTON--Scientists at Dana-Farber Cancer Institute have identified a subtype of ovarian cancer able to build its own blood vessels, suggesting that such tumors might be especially susceptible to "anti-angiogenic" drugs that block blood vessel formation.
            • Ovarian Cancer Screening: Are Doctors Ordering Too Many Tests?
              No major medical organizations recommend routine ovarian cancer screening, but that hasn't stopped doctors from regularly testing for the disease.

                 Related on Wikipedia




























               

              Powered free by PHPmotion